Keywords: Shire, Vpriv, FDA, Gaucher disease, Genzyme, Cerezyme

US FDA clears Shire’s Vpriv for Type 1 Gaucher disease

Article | 01 March 2010

Print This

The US Food and Drug Administration has granted marketing approval for UK drugmaker Shire’s Vpriv (velaglucerase alfa for injection), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in